November 18, 2026

An accelerating Ebola outbreak puts hope in two new vaccines in testing

The World Health Organization has announced an anticipated medical development, which is the start of testing two experimental vaccines to combat the deadly “Bundebugyo” strain of the Ebola virus in the Democratic Republic of the Congo, starting next week, in a step aimed at controlling the accelerating outbreak that has claimed the lives of thousands.

The Director-General of the Organization, Tedros Adhanom Ghebreyesus, explained during a press conference held in Geneva that this step comes within the framework of expanding the clinical trials underway in the country. A vaccine developed by the University of Oxford in cooperation with the Indian Serum Institute, and another developed by the Moderna company, is expected to be introduced after completing the required approvals, to be coupled with the experiments that were launched last October using the previously approved “Ervibo” vaccine against other strains.

The Democratic Republic of the Congo has been facing a stifling health crisis since the official announcement of the outbreak of the epidemic on May 15, 2026 as a result of infection with the “Bundibugyo” strain, which so far does not have any vaccine or treatment approved specifically for it. The latest data recorded until November 14, 2026 showed the total number of confirmed infections reaching 11,376 cases, of which 5,568 people died in just six months.

Tedros warned that between 400 and 500 new infections would continue to be recorded weekly, drawing attention to a worrying indicator that about two-thirds of deaths occurred outside treatment centers, which reflects the delay in discovering infections and reaching medical care. The complexities of the health scene are multiplied by the spread of the virus in new areas, amid security and humanitarian challenges that hinder the work of medical teams in reaching those affected and tracing contacts.

As the medical community awaits the emergence of the initial results of vaccine trials in early 2027, the World Health Organization stresses that research, despite its strategic importance, remains in constant need of urgent measures that include early detection, isolating patients, tracing contacts, and providing the necessary care to contain the epidemic and reduce human losses.